Univariant analysis revealed that the insulin receptor content of the tumors correlated positively with tumor size (P = 0.014), histological grading (P = 0.030), and the estrogen receptor content (P = 0.035). There were no significant correlations between insulin receptor content and the age, body weight, menopausal status, and nodal involvement of the patients. These studies indicate, therefore, that the insulin receptor content is increased in breast cancers and raise the possibility that the insulin receptor may have a role in the biology of these tumors. (J. Clin. Invest. 1990Invest. . 86:1503Invest. -1510
Introduction
Human and animal breast carcinomas have receptors for steroid and peptide hormones (1) (2) (3) (4) (5) (6) (7) (8) (9) , and both in vitro and in vivo studies (1, (10) (11) (12) (13) (14) (15) indicate that their growth is hormone dependent. Various studies have demonstrated that there is a greater long term survival in patients with breast carcinomas Received for publication 16 October 1989 and in revisedform 12 July 1990. that have receptors for estrogen and progesterone, and in these patients tumor growth can be decreased by a variety of manipulations that alter steroid hormone levels (16) (17) (18) (19) . However, some patients with breast carcinomas containing high concentration of estrogen and progesterone receptors do not show beneficial responses to hormonal therapy ( 16, 20) . One explanation for this unresponsiveness is that the tumor cells, for a variety of reasons, may have escaped from hormonal regulation. A second explanation is that these tumors are heterogeneous and contain subpopulations of cells without steroid hormone receptors. A third explanation is that tumor cells contain receptors for other classes of hormones such as polypeptide hormones and growth factors, and that these hormones, either by themselves or in combination with steroid hormones, stimulate tumor growth (1, 21) . For this reason, it is of importance to identify in breast cancer cells the presence of receptors for other hormones and growth factors that may influence the behavior/evolution of the tumor.
Insulin regulates the growth and metabolism of animal breast cancer cells both in vivo and in vitro (22-24) and human breast cells in vitro (23, (25) (26) (27) (28) . Moreover, several human breast cancer cell lines in permanent culture have specific, high-affinity receptors for insulin (29, 30) , and the presence of insulin receptors has been reported in frozen specimens of human breast carcinomas (4, 31) . For several reasons, however, the importance of these observations is unclear. First, a quantitative comparative analysis between the number of receptors in tumor cells versus normal mammary gland tissue has not been carried out. Second, in human cancers, correlations between insulin receptor content, and established prognostic parameters of cancer evolution including estrogen and progesterone receptor content, and tumor size and grading have not been made.
Recently, we have developed a highly sensitive and specific RIA for the insulin receptor (32) . This assay allows the precise quantitation of the insulin receptor in very small tissue specimens and does not significantly cross react (< 3%) with the related insulin-like growth factor (IGF-I)' receptor (32) . In (35) . The grading ofinfiltrating ductal and mixed carcinomas was assessed on a scale of 1 (well-differentiated) to 3 (poorly differentiated) taking into account the degree of tubular differentiation, the nuclear pleomorphism and the mitotic activity according to Bloom and Richardson (36) . On 10,000 g for 5 min at 4VC in a microfuge (Beckman Instruments Inc., Palo Alto, CA) and the supernatant frozen at -80'C until assayed. MCF-7 human cultured breast cancer cells were solubilized for radioimmunoassay as previously described for cultured cells (32) .
'25I-insulin binding to solubilized receptors. Binding studies were carried out with solubilized insulin receptors (30 ng) in a final volume of0.5 ml ofbuffer containing 1D)0 mM Hepes (pH 7.9), 120 mM NaCl, 1.2 mM MgCl2, 2 mM MnCl2, 2.5 mM KCl, 0.5 mM Na acetate, 1 mM EDTA, 1 mg/ml bacitracin, and 10 mg/ml BSA. '251-insulin (66 pM) was added in the presence or absence of excess unlabeled insulin (166 nM) and incubated for 18 h at 4VC. Carrier human gamma globulin (2 mg/ml) was added to each tube, 0.5 ml of 22% PEG 6,000 was then added and incubated for 15 min at 4°C. After centrifugation, precipitates were washed once with 11% PEG, recentrifuged, the supernatants discarded, and the pellets counted. Specific binding was obtained by subtracting binding with '25I-insulin plus unlabeled insulin from binding with '25I-insulin alone.
Insulin receptor RIA. The insulin receptor radioimmunoassay was performed as previously described (32) . Briefly, the following reagents were added to 9 X 70 plastic tubes: 0.2 ml of either solubilized tissues, or buffer (50 mM Hepes, pH 7.6, 150 mM NaCl, 0.1% Triton X-100, 0.2% BSA, and 0.2 mM PMSF) containing 0-15 ng of unlabeled receptor; 0.1 ml of the same buffer containing the antiinsulin receptor antiserum (final dilution 1:100,000) and nonimmune rabbit serum (final dilution 1:400). After 16 h at 4°C, 6,000-8,000 cpm of '25I-labeled insulin receptor labeled with Bolton-Hunter reagent (sp act, 2,100-3,200 Ci/mMol) (32) were added in 0.1 ml of buffer. After a further 24 h incubation, 0.1 ml of goat anti-rabbit gamma globulin serum were added (final dilution 1:150). The reaction was allowed to incubate further 24 h at 4°C, and then centrifuged at 3,000 g for 25 min. The supernatants were aspirated, and the precipitated radioactivity counted. The receptor content of the specimens was expressed as nanograms of insulin receptors/0. 1 mg of either protein or DNA. This assay is sensitive to unlabeled receptor concentration as low as 1.0 ng/ml; the interassay coefficient ofvariation is 9.0% and the intraassay variation is 5.0%. The cross-reactivity with the IGF-I receptor is < 3%.
Insulin receptor tyrosine kinase assay. Phosphotransferase activity of wheat germ agglutinin-purified insulin receptors was determined by preincubating 10 ng ofreceptors with various concentrations ofinsulin for 60 min at 22°C in a buffer containing 50 mM Hepes (pH 7.4), 0.1% Triton X-100, 150 mM NaCI, 1 mM PMSF. Next, 2 mM MnCl2, 10 mM MgCl2 and 5 MM ['y-32P]ATP (2 MCi/tube) were added for 30 min at 22°C in the presence of 1 mM Na3VO4 to inhibit dephosphorylation reactions. The synthetic substrate poly(Glu-Tyr, 4:1) was then added to a final concentration of 2.5 mg/ml, and the incubation continued for 30 min at 22°C. Finally, 40 ,d aliquots were spotted on 4-cm2 disks of 3 M paper (Whatman Inc., Clifton, NJ) and dried. Disks were washed in four changes of 10% TCA containing 10 mM sodium pyrophosphate and in a final acetone wash. Radioactivity was determined by scintillation counting. The background controls were determined from duplicate reactions lacking poly(Glu-Tyr).
Immunostaining. Specimens of normal breast tissue and breast cancer were fixed in Bouin's solution and embedded in paraffin. Sections of -5 grm thick were cut for staining. Counterstaining was with Harris hematoxylin. Immunoperoxidase staining was performed as described by Sternberger (37) as previously reported (38) . After the sections were deparaffined by xylol treatment, they were incubated 2 h at 24°C with either normal mouse IgG or insulin receptor monoclonal antibody each at 7 nM. This incubation was followed by incubation with 1/1,000 anti-mouse IgG peroxidase for 30 min at 24°C. After rinsing, the peroxidase activity was demonstrated by a solution of 225 ,uM diaminobenzidine buffer with 0.01% H202. A (Fig. 2) . These studies demon- Fig. 2 ). The average strated, therefore, that breast cancer tissue had high levels of rast carcinoma specimmunoreactive insulin receptors. -in (mean±SD; meFunctional studies ofthe breast cancer insulin receptor. We next carried out studies to determine whether these immunoreactive insulin receptors in breast cancer tissue were functional. First, the ability of these insulin receptors to bind insulin was investigated. Sufficient tissue was available from six normal breast tissue specimens and 6 breast cancer tissue specimens to perform ligand binding studies. Solubilized receptors from normal breast tissues bound 0.51±0.30% (mean±SD) of (Table I) .
Second, the tyrosine kinase activity of the breast cancer a insulin receptor was studied. The ability of partially purified io joo breast cancer and normal breast IR preparations from the same patient to phosphorylate the exogenous synthetic substrate poly(Glu-Tyr, 4:1) was measured (Table II) . Normal -I---------+----Ibreast and breast carcinoma IRs had both similar basal tyro-100 500 sine kinase activity, and insulin stimulated this function in a dose dependent manner (Table II) . purified placenta inMorphological localization ofthe breast cancer insulin rean MCF-7 breast ceptor. We next investigated which cell type contained insulin rmal breast tissue (9) receptors in the breast cancer specimens. Surgical specimens of tireceptor antiserum. insulin receptors, immunohistochemical analysis using a monoclonal antibody to the alpha subunit ofthe human insulin receptor (33) was carried out in six breast cancer specimens. This analysis clearly showed an intense cytoplasmic/membrane staining in 100% ofthe tumor epithelial cell nests. There was, however, occasional differences in staining between cells suggesting heterogeneity in IR content. On the contrary, no specific immunostaining for the insulin receptor was seen in the stromal or inflammatory cells (Fig. 3) . Little or no staining ofthe epithelial cells ofnormal breast tissue was observed (data not shown). This latter observation most likely reflects the sevenfold decreased IR content in normal breast tissue.
Correlations (43)
To assess whether the IR content was related to other characteristics of the breast tumors, we first examined the distribution of IR. The scatter diagram in Fig. 2 (Fig. 4) . The frequency histogram in Fig. 4 contents of IR to other variables. These were grouped into three categories; host variables (age, body mass index, and menopausal status), tumor variables (histological type, grade, size, and nodal involvement), and other hormone receptors (estrogen receptor and progesterone receptor). Relationship ofIR to host variables. Three host variables, patient's age, body mass index, and menopausal status, were obtained for 156, 138, and 156 patients, respectively. The patient's age was only modestly correlated with the IR values (r -0.14; P = 0.85).
Of the 156 patients whose menopausal status could be ascertained, there were 44 (28.2%) who were premenopausal and 112 (71.8%) who were postmenopausal. The values for IR in the pre and post menopausal groups, were 5.0±1.7 and 5.3±1.7 0.1 ng/mg protein respectively (mean±SD) (P = 0.63). Body mass index did not correlate with IR (r = 0.02, P = 0.42).
Relationship ofIR to tumor properties. Information about histological type was available for 149 (93.7%) of the tumors (Table III) . No difference was seen between the five categories. Classification of tumors according to grade was performed in 121 specimens of ductal and mixed carcinomas. The IR content in the three groups was 4.5±1.2 (n = 5), 4.8±1.7 (n = 73), and 6.2±1.6 (n = 43) ng IR/0. 1 mg protein in the (a) well, (b) middle, and (c) poorly differentiated tumors, respectively (mean±SD). Although there was considerable overlap between the distributions of IR in these three categories, by one-way analysis of variance (ANOVA) (Fig. 5 A) , the mean level in the undifferentiated category (c) was significantly higher than from the mean values observed in the other two categories (P -0.003).
Nodal involvement was known in 131 patients: no relationship was found between IR content and nodal involvement (Fig. S B) . The group of61 node negative patients had an insulin receptor content of 5.1±1.8 ng/0. 1 mg protein and the group of 70 node positive patients had an IR content 5.7±1.7 ng/0.1 mg protein (mean±SD). These differences were not statistically significant.
We next studied the relationship between IR and tumor size (Fig. 5 C) . The IR content in three groups (< 2 cm, 2-5 cm, and > 5) were 4.6±1.6, 6.0±1.8, and 6.4±1.8 ng IR/0.1 mg protein, respectively (mean±SD). According to one-way ANOVA, the mean IR content increase related to tumor size could not be explained by chance alone (P = 0.0 14).
Relationship of IR to other hormone receptor levels. The
Spearman correlations between insulin receptor measurements and estrogen and progesterone receptors, were 0.17 (P = 0.035) and 0.10 (P = 0.20), respectively. Other studies To ascertain whether elevated insulin receptors were present in glandular malignancies other than breast cancer, we also evaluated the insulin receptor content in nonmalignant thyroid tissue specimens, and thyroid carcinomas. No difference in insulin receptors was found between thyroid carcinomas and nonmalignant thyroid tissues (Table IV) .
Discussion
In the present study, we have employed a specific RIA to measure insulin receptor content in samples of breast carcinoma tissues from 159 patients. The measurement of insulin receptors by radioimmunoassay has certain advantages over (44, 45) . A second possibility is that the expression of the IR in fact does vary between malignant breast epithelial cells in different tumor specimens. (47) . The receptors for both (IGF-I) and epidermal growth factor (EGF) have been reported to be elevated in some, but not all tumors (47) . Also the HER 2/neu protein, a putative receptor closely related to the EGF receptor, is elevated in 25-30% of breast cancers (45) . In a recent study, tyrosine kinase activity was measured in human breast cancers and was found to be significantly increased when compared to benign breast tumors and normal breast tissue (48) . Our present observation of an insulin responsive insulin receptor tyrosine kinase activity in breast cancers indicates that, in addition to EGF, IGF-I, and HER 2/neu receptors, another contribution to the increased tyrosine kinase activity in breast cancer is from the increased insulin receptor content.
Studies reveal that the ligand for the IGF receptor, IGF-I, is produced by breast cancer stromal cells (49) . Thus, a paracrine relationship for this ligand-receptor system may exist in certain breast carcinomas and contribute to increased cancer agressiveness. The IGF-I receptor has sequence and structural homology to the insulin receptor, and IGF-I has sequence and structural homology to insulin. Moreover, IGF-I can also interact with and activate the insulin receptor. Thus, a paracrine relationship may exist whereby IGF-I stimulates insulin receptors in breast cancer leading to increased insulin receptor signaling.
The mechanism(s) whereby insulin receptors are increased in human breast cancers remain speculative. There are several possibilities. Since the genes for some oncogenes including c-myc, int-2, c-erbB-2 and the related HER-2/neu may be amplified in human breast carcinomas (44) , it is possible that the insulin receptor gene is also amplified. Alternatively, since structural gene rearrangement occurs in human breast carcinomas (50) , it is possible that the insulin receptor gene is altered in this tumor and consequently insulin receptor mRNA is overexpressed.
The clinical significance of the observation that insulin receptors are markedly elevated in nearly all breast cancer specimens analyzed is unknown. In the present study, analysis of IR content was correlated with other parameters. On one hand, in ductal and mixed tumors there was a significant correlation with IR and tumor grading, tumor properties reflecting tumor agressiveness. There was also a significant correlation with IR and tumor size. Tumor size most likely reflects both inherent tumor aggressiveness and the duration of tumor growth. These two observations suggested therefore that less differentiated and more aggressive tumors may have more insulin receptors. The possibility also exhibits, however, that the duration of tumor growth may lead to the selection of cancer cells with a higher IR content. On the other hand, there was not a correlation with IR content and lymph node involvement, another reflection of tumor aggressiveness and duration of tumor growth. Also, there was a significant positive correlation with IR content and estrogen receptor content, a favorable prognostic indicator. Since insulin regulates breast cancer cell growth, and insulin receptors are elevated in breast cancer tissues, it is likely that insulin and its receptor plays a role in breast cancer biology. However, whether IR content predicts a negative or positive outcome in these tumors remains to be elucidated. These observations, although obtained in a limited number of patients, raise the possibility, therefore, that the insulin receptor may play a role in the biology ofbreast cancers and that measurement of the insulin receptor content should be useful, in conjunction with other parameters, in the classification of breast tumors.
